BIOAGE LABS INC (BIOA) Stock News
NASDAQ:BIOA - Nasdaq - US09077V1008 - Common Stock - Currency: USD
BIOA Latest News, Press Relases and Analysis
BioAge Labs to Present Preclinical Data on APJ Agonism for Diabetic Obesity and Heart Failure at the American Diabetes Association (ADA) 85th Scientific Sessions
Treatment with apelin receptor agonist enhanced glycemic control and demonstrated cardioprotective effects, with additive benefits observed in combination...
BioAge Labs to Present at Upcoming Investor Conferences
EMERYVILLE, Calif., May 27, 2025 (GLOBE NEWSWIRE) -- BioAge Labs, Inc. (NASDAQ: BIOA) (
BioAge Labs Expands Drug Discovery Platform with Data from Leading European Biobank
Company to generate and analyze molecular profiles from over 17,000 samples from the HUNT Biobank in Norway to accelerate discovery of drug targets for...
BioAge Labs Expands Drug Discovery Platform with Data from Leading European Biobank
BioAge Expands APJ Agonist Pipeline with Oral Small-Molecule and Long-Acting Biologic Candidates
Company enters option agreement with JiKang Therapeutics to in-license novel APJ agonist antibody New composition of matter IP filed for chemically...
BioAge Expands APJ Agonist Pipeline with Oral Small-Molecule and Long-Acting Biologic Candidates
H.C. Wainwright Initiates Coverage of Trevi Therapeutics (TRVI) With Buy Rating
On May 28, Oren Livnat, an analyst from H.C. Wainwright initiated coverage of Trevi Therapeutics, Inc. (NASDAQ:TRVI) with a Buy rating and a $21 price target. The update comes after the company released additional analysis from the Phase 2a RIVER trial of Haduvio in patients with Refractory Chronic Cough. The company released additional analysis from […]
BioAge Labs completes IND-enabling studies for BGE-102, a potent, orally available, brain-penetrant NLRP3 inhibitor, and advances candidate toward the clinic
IND submission planned for mid-2025 with Phase 1 SAD data anticipated by year end BGE-102 induced weight loss in preclinical obesity models, both as...
BioAge Labs to Present at Upcoming Investor Conferences
BioAge Labs Reports First Quarter 2025 Financial Results and Provides Business Updates
Advancement of lead candidate BGE-102, an oral, brain-penetrant NLRP3 inhibitor for obesity, with initial clinical data expected 2H25New strategic...
BioAge Labs Reports First Quarter 2025 Financial Results and Provides Business Updates
BioAge Labs, Inc. (BIOA): A Bull Case Theory
We came across a bullish thesis on BioAge Labs, Inc. (BIOA) on Substack by Ragnarok Research. In this article, we will summarize the bulls’ thesis on BIOA. BioAge Labs, Inc. (BIOA)’s share was trading at $3.87 as of April 17th. BioAge Labs (BIOA) represents a classic “cigarette butt” investment—an overlooked and beaten-down company that still has a […]
Booking Holdings Inc. (BKNG): A Bull Case Theory
We came across a bullish thesis on Booking Holdings Inc. (BKNG) on Substack by Jimmy Investor. In this article, we will summarize the bulls’ thesis on BKNG. Booking Holdings Inc. (BKNG)’s share was trading at $4573.31 as of April 17th. BKNG’s trailing and forward P/E were 26.48 and 21.79 respectively according to Yahoo Finance. The travel industry […]
BioAge Labs Reports Full Year 2024 Financial Results and Provides Business Updates from the Fourth Quarter of 2024
Advancement of oral, brain-penetrant NLRP3 inhibitor BGE-102, with initial clinical data expected 2H25 Progression of preclinical next-generation APJ...
BioAge Labs Reports Full Year 2024 Financial Results and Provides Business Updates from the Fourth Quarter of 2024
Final Deadline for the BioAge Labs, Inc. Securities Lawsuit - Contact the DJS Law Group to Discuss Your Rights - BIOA
/PRNewswire/ -- The DJS Law Group reminds investors of a class action lawsuit against BioAge Labs, Inc. ("BioAge" or "the Company") (NASDAQ: BIOA) for...
BIOA Deadline Today: BIOA Investors Have Opportunity to Lead BioAge Labs, Inc. Securities Lawsuit
/PRNewswire/ -- Why: Rosen Law Firm, a global investor rights law firm, reminds purchasers of stock of BioAge Labs, Inc. (NASDAQ: BIOA) pursuant and/or...
BIOA Investors Have Opportunity to Lead BioAge Labs, Inc. Securities Fraud Lawsuit with the Schall Law Firm
BioAge Labs, Inc. Class Action: The Gross Law Firm Reminds BioAge Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of March 10, 2025 - BIOA
/PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of BioAge Labs, Inc. (NASDAQ: BIOA). Shareholders who purchased shares of BIOA...
Deadline Soon: BioAge Labs, Inc. (BIOA) Investors Who Lost Money Urged To Contact The Law Offices of Frank R. Cruz About Securities Fraud Lawsuit
Faruqi & Faruqi Reminds BioAge Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of March 10, 2025 - BIOA
BIOA Deadline in 4 Days: Kessler Topaz Meltzer & Check, LLP Reminds BioAge Labs, Inc. (BIOA) Investors of Filing Deadline in Class Action Lawsuit
/PRNewswire/ -- The law firm of Kessler Topaz Meltzer & Check, LLP (www.ktmc.com) informs investors that a securities class action lawsuit has been filed...
INVESTOR DEADLINE MONDAY: BioAge Labs, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit - BIOA
/PRNewswire/ -- The law firm of Robbins Geller Rudman & Dowd LLP announces that purchasers or acquirers of BioAge Labs, Inc. (NASDAQ: BIOA) stock pursuant...
The Gross Law Firm Notifies Shareholders of BioAge Labs, Inc.(BIOA) of a Class Action Lawsuit and an Upcoming Deadline
/PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of BioAge Labs, Inc. (NASDAQ: BIOA). Shareholders who purchased shares of BIOA...
BIOA Deadline: BIOA Investors Have Opportunity to Lead BioAge Labs, Inc. Securities Lawsuit
/PRNewswire/ -- Why: Rosen Law Firm, a global investor rights law firm, reminds purchasers of stock of BioAge Labs, Inc. (NASDAQ: BIOA) pursuant and/or...